Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) released its earnings results on Tuesday. The company reported ($3.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35, FiscalAI reports. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $0.82 million.
Bolt Biotherapeutics Trading Down 2.5%
Shares of BOLT stock opened at $4.69 on Thursday. Bolt Biotherapeutics has a 12-month low of $4.42 and a 12-month high of $13.00. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $5.46 and a two-hundred day moving average price of $5.82. The firm has a market cap of $9.00 million, a P/E ratio of -0.18 and a beta of 0.93.
Wall Street Analyst Weigh In
BOLT has been the subject of several recent analyst reports. HC Wainwright set a $7.00 price objective on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a research note on Monday, October 20th. Lake Street Capital boosted their price target on shares of Bolt Biotherapeutics to $75.00 and gave the company a “buy” rating in a research report on Friday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Finally, Zacks Research raised Bolt Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
Further Reading
- Five stocks we like better than Bolt Biotherapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- As Warren Buffett Nears His Exit, Berkshire’s Amassed Record Cash
- The Basics of Support and Resistance
- Rare Earth Stocks: The Truce That Isn’t a Truce
- How to Invest in Blue Chip Stocks
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
